One-Liner
An institutional-grade AI-drug-only pipeline tracker with probabilistic forecasting for long-short biotech hedge funds at $15–25K/year.
AI Thinking Process
Institutional B2B variant of Thread 2. Long-short biotech hedge funds want full AI-drug pipeline visibility + probabilistic forecasting at $15-25K/year. BioMed Nexus is $5K/year.
BioMed Nexus AI Drug Tracker — direct competitor at $5K/year. Citeline at $30K/year (broader). Individual company IR newsletters (single company). Pharmcube (Chinese-language). BioMed Nexus is the direct institutional incumbent.
CURRENT failed: long-short funds already have BioMed Nexus AI Drug Tracker ($5K/year) for pipeline tracking. There is no manual/painful behavior I'm displacing — they already pay a direct competitor.
BioMed Nexus is incumbent direct competitor at lower price than the position contemplated. Probabilistic forecasting differentiation is 6-month BioMed Nexus feature. Killed.
Kill Reason
BioMed Nexus AI Drug Tracker is the direct incumbent at $5K/year with institutional-grade pipeline tracking. Long-short biotech funds already pay BioMed Nexus — there is no manual/painful/expensive current behavior to displace. The probabilistic forecasting differentiation is something BioMed Nexus could ship in 6 months using the same public clinical-trial datasets.
Risk Analysis
Risk analysis available for latest engine ideas.
What do you think?
Related ideas you can explore free:
killed: BioMed Nexus AI Drug Tracker is the direct incumbent at $5K/year with institutional-grade pipeline tracking. Long-short biotech funds already pay BioMed Nexus — there is no manual/painful/expensive current behavior to displace. The probabilistic forecasting differentiation is something BioMed Nexus could ship in 6 months using the same public clinical-trial datasets.
killed: Open-source middleware (HAMi) already provides heterogeneous AI computing virtualization for free. Proprietary play is squeezed between free open-source and vertically integrated hardware vendor ecosystem.
killed: 5+ funded competitors including Cast AI ($1B valuation), OneChronos (backed by Nobel laureate), Akash Network (decentralized, 80% cheaper), Argentum AI (blockchain-settled). Market is claimed with massive capital.